Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

Malignant Neoplasm of Breast

Open-data reference.

11 US clinical trials · 3 currently recruiting

Active & Recent Trials

RECRUITING NA 175 participants

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

National Cancer Institute (NCI)

NCT07067138

RECRUITING NA 122 participants

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

Novian Health

NCT03463954

RECRUITING Phase 1 20 participants

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Calibr, a division of Scripps Research

NCT06878248

ACTIVE NOT RECRUITING Phase 1 90 participants

Selumetinib and Olaparib in Solid Tumors

M.D. Anderson Cancer Center

NCT03162627

ACTIVE NOT RECRUITING NA 62 participants

An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer

M.D. Anderson Cancer Center

NCT03429907

ACTIVE NOT RECRUITING Phase 1 34 participants

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

US Oncology Research

NCT03379428

ACTIVE NOT RECRUITING Phase 1 27 participants

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Washington University School of Medicine

NCT02204098

ACTIVE NOT RECRUITING Phase 1 18 participants

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

M.D. Anderson Cancer Center

NCT03435952

ACTIVE NOT RECRUITING 1 participants

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Pfizer

NCT06495164

COMPLETED NA 41 participants

Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

Washington University School of Medicine

NCT02891681

COMPLETED Phase 2 26 participants

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

HiberCell

NCT05159778

Phase Distribution

PhaseTrial count
Early Phase 1 5
Phase 2 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Malignant Neoplasm of Breast Trial Landscape

ClinicalTrials.gov lists 11 US studies indexed under Malignant Neoplasm of Breast, and 3 of those are currently open to recruitment — roughly 27% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Malignant Neoplasm of Breast shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 6 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Malignant Neoplasm of Breast is led by M.D. Anderson Cancer Center with 3 indexed trials, alongside 7 other organizations in the top contributor list. The list on this page surfaces up to 11 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Malignant Neoplasm of Breast?

PlainTrial tracks 11 US clinical trials for Malignant Neoplasm of Breast, of which 3 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Malignant Neoplasm of Breast?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →